Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesAngiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies
EurekAlert, 10/19/09
Angiochem, Inc. a clinical–stage biotechnology company developing drugs that are uniquely capable of crossing the blood–brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. These data, which validates in humans Angiochem's peptide–based platform technology (EPiC), were presented at the Society for Neuroscience Annual Meeting in Chicago on October 18, 2009.
Today in Popular Press...keeping you current
Receive free subspecialty "5-minute updates" via email
Easily led ash-tray: Adolescent smokers prone to drug abuse
EurekAlert, 12/14/09
Pathological gambling may be successfully treated with medications for substance addiction
EurekAlert, 12/11/09
Irregular arm swing may point to Parkinsons disease
ScienceDaily, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor